Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

Volcano acquires Xtract Thrombus Aspiration Catheter device from Lumen Biomedical

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedical.

9 Feb 2010

Simple, inexpensive test for diagnosing cardiac-related chest pain

Researchers at the Methodist DeBakey Heart & Vascular Center have shown that a simple, inexpensive test can determine whether it is safe to send home a patient who comes to the emergency room with chest pain.

9 Feb 2010

Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule

Resverlogix Corp. announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic.

9 Feb 2010

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.

8 Feb 2010

Stereotaxis Magnetic Navigation System installed at CHMC, Taiwan

Stereotaxis today announced the installation of its first Stereotaxis Magnetic Navigation System in Taiwan at Cheng-Hsin General Hospital (CHMC) located in Taipei. CHMC hosted a Grand Opening event on January 26 that received wide coverage throughout the area and, to date, ten procedures have been successfully performed using Stereotaxis at the hospital.

8 Feb 2010

Tracking early signs of coronary artery clogs: CT perfusion vs. SPECT nuclear imaging tests

Cardiologists and heart imaging specialists at 15 medical centers in eight countries, and led by researchers at Johns Hopkins, have enrolled the first dozen patients in a year-long investigation to learn whether the subtle squeezing of blood flow through the inner layers of the heart is better than traditional SPECT nuclear imaging tests and other diagnostic radiology procedures for accurately tracking the earliest signs of coronary artery clogs.

5 Feb 2010

Personalized risk assessment tools can help improve smoking cessation

Giving smokers information about their own individual risk of serious illness helps motivate them to quit smoking, according to a paper published in the current issue of Postgraduate Medical Journal.

5 Feb 2010

CCHP implements TriZetto systems to improve its network and health management programs

The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.

5 Feb 2010

Vanderbilt Heart and Vascular Institute offers new blood test to predict heart disease

Just in time for American Heart Month, Vanderbilt Heart and Vascular Institute is offering a new blood test that can predict if a patient is at high risk for heart disease. Vanderbilt is among the first institutions in the country, and the only one in Tennessee, to offer this test.

5 Feb 2010

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

Major study of perfusion imaging under way to assess value of alternative diagnostic methods

3 Feb 2010

Cardiac catheterization: A groundbreaking tool in the field of cardiology

Cardiac catheterizations have been a groundbreaking tool in the field of cardiology. This procedure offers a minimally invasive means for obtaining important information about the heart and its blood vessels, while also providing a less invasive treatment for certain heart conditions.

2 Feb 2010

Obesity and type 2 diabetes in younger people can increase risk of stroke and heart attack

People who are obese and have type 2 diabetes in their 20s will be at higher risk of having a heart attack or stroke in their 40s if they do not change their lifestyle.

30 Jan 2010

How to recognize heart attack symptoms in younger women

The risk for heart-related death is increasing in young adults ages 35 to 54, and the numbers are even more alarming for younger women. It is the number-one cause of death for both men and women in the United States, yet every year since 1984 more women have died of cardiovascular health problems than men, according to the American Heart Association.

29 Jan 2010

FDA approves LPI's Perindopril Erbumine tablets

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Perindopril Erbumine tablets, 2mg, 4mg and 8mg. Commercial shipments of the product will commence shortly.

29 Jan 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders.

28 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

Update on Cardium Therapeutics' plans for commercial development of Generx

Cardium Therapeutics reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease.

27 Jan 2010

Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development

Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.

27 Jan 2010

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Volcano acquires Xtract Thrombus Aspiration Catheter device from Lumen Biomedical

Simple, inexpensive test for diagnosing cardiac-related chest pain

Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

Stereotaxis Magnetic Navigation System installed at CHMC, Taiwan

Tracking early signs of coronary artery clogs: CT perfusion vs. SPECT nuclear imaging tests

Personalized risk assessment tools can help improve smoking cessation

CCHP implements TriZetto systems to improve its network and health management programs

Vanderbilt Heart and Vascular Institute offers new blood test to predict heart disease

Study: Generic nifedipine product not bioequivalent to Adalat XL

Major study of perfusion imaging under way to assess value of alternative diagnostic methods

Cardiac catheterization: A groundbreaking tool in the field of cardiology

Obesity and type 2 diabetes in younger people can increase risk of stroke and heart attack

How to recognize heart attack symptoms in younger women

FDA approves LPI's Perindopril Erbumine tablets

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Abbott declares quarterly dividend of 40 cents per share

Update on Cardium Therapeutics' plans for commercial development of Generx

Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in